Search clinical trials for: PF-04950615 Dose A

Total 551 results

Pfizer

Completed

A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects

Hypercholesterolemia

United States
Pfizer

Completed

Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin

Hypercholesterolemia

United States
Pfizer

Completed

A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States
Pfizer

Completed

A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers

Healthy

United States
Pfizer

Completed

STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS

Healthy Participants

United States, Belgium
Pfizer

Completed

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins (SPIRE-SI)

Hyperlipidemia

United States, Canada
Pfizer

Completed

PF-06651600 for the Treatment of Alopecia Areata (ALLEGRO-2b/3)

Alopecia Areata

China, United States, Spain, Korea, Republic of, Taiwan, Canada, Australia, Germany, Czechia, Poland, Hungary, Japan, United Kingdom, Argentina, Chile, Colombia, Mexico, Russian Federation
Pfizer

Completed

Study in Healthy Adults Evaluating PF-07202954

Liver Fibrosis | Non-Alcoholic Fatty Liver Disease

United States
Pfizer

Completed

A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy

Type 2 Diabetes Mellitus

Japan
Pfizer

Completed

A Study to Investigate the Effect of Tablet Formulation and Food on PF-07104091 in Healthy Participants

Healthy

United States
Pfizer

Completed

A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease

Respiratory Tract Diseases | Lung Diseases | Pulmonary Disease, Chronic Obstructive | COPD | Chronic Obstructive Airway Disease

Germany
Pfizer

Completed

Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.

Ocular Hypertension | Primary Open-Angle Glaucoma

United States
Pfizer
Trans Tech Pharmaceuticals

Completed

A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients

Alzheimer Disease

United States
Pfizer

Withdrawn

The Bioavailability of a Spray Dried Dispersion Solid Dose Formulation of PF-06260414 Relative to a Suspension Formulation

Healthy

United States
Pfizer

Completed

A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia

Metabolic Diseases | Dyslipidemias | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias

United States
Pfizer

Terminated

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

Parkinson Disease

United States, Spain, Canada, France, Japan, Germany
Kadmon Corporation, LLC

Completed

Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors

Cancer

United States
University of California, San Francisco
Pfizer; San Francisco General Hospital

Terminated

Bococizumab HIV Evaluation (B-HIVE) Study (B-HIVE)

Cardiovascular Disease | Dyslipidemia

United States
Pfizer

Completed

Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia

Dyslipidemia | Hypercholesterolemia

United States
Pfizer

Completed

6-week Safety and PD Study in Adults With NAFLD

Non-alcoholic Fatty Liver Disease

United States
Pfizer

Terminated

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-1)

Cardiovascular Disease

Finland, United States, Netherlands, Spain, Korea, Republic of, China, Israel, Belgium, Germany, Australia, Czechia, Taiwan, Denmark, United Kingdom, Hungary, Poland, France, Mexico, Turkey, Canada, New Zealand, Colombia, Switzerland, Irelan... and more
Pfizer

Completed

Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm

Hypercholesterolemia

United States
Pfizer

Completed

Clinical Trial In Healthy Volunteers And Health Elderly Volunteers To Evaluate The Safety, Tolerability And Blood Concentration After Single And Multiple Escalating Oral Doses Of PF-06751979.

Healthy Subjects

Belgium
Pfizer

Completed

First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979

Healthy Subjects

United States
Pfizer

Completed

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events (SPIRE-LL)

Hyperlipidemia

Finland, Netherlands, United States, Canada, Sweden, Korea, Republic of, Singapore, Czechia, Poland, United Kingdom, Puerto Rico, Norway
Pfizer

Completed

OPEN LABEL, 2-PERIOD STUDY, TO COMPARE BIO-AVAILABILITY OF 2 DIFFERENT FORMULATIONS OF PF-05221304 IN HEALTHY ADULTS

Healthy

United States
Pfizer

Terminated

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-2)

Cardiovascular Disease

United States, Finland, Netherlands, Spain, Belgium, Germany, Czechia, Switzerland, Denmark, Australia, United Kingdom, Korea, Republic of, Hungary, Israel, Poland, Taiwan, Mexico, Turkey, Ireland, Canada, New Zealand, South Africa, Brazi... and more
Pfizer

Completed

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events (SPIRE-LDL)

Hyperlipidemia

United States, Spain, Taiwan, United Kingdom, Canada, Mexico, France, Hungary, Lithuania, Colombia, Romania, Russian Federation
Pfizer

Completed

A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia (SPIRE-FH)

Heterozygous Familial Hypercholesterolemia

Canada, Netherlands, United Kingdom, United States, Spain, Poland, Finland, Norway, South Africa, Italy, Bulgaria
Pfizer

Completed

Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events (SPIRE-HR)

Hyperlipidemia

Korea, Republic of, United States, Australia, Germany, Poland, Canada, Italy, Hong Kong, Czech Republic
Pfizer
Thrombolysis In Myocardial Infarction (TIMI)

Recruiting

A Study of Ponsegromab in People With Heart Failure (GARDEN TIMI 74)

Heart Failure

United States, Canada, China, Australia, Spain, Japan, Czechia, Hungary, Germany, United Kingdom, Poland
Pfizer

Recruiting

A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults

Healthy Participants

United States
Pfizer

Completed

A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins

Dyslipidemia | Hypercholesterolemia

United States, Canada
Pfizer

Completed

A Study to Understand the Effect of Low-Fat and High-Fat Meals on the Medicine Called PF-07284890 in Healthy Adults

Healthy Participants

United States
Pfizer

Completed

A Preliminary Study to Evaluate PF-07264660 in Healthy Participants

Healthy

United States
Pfizer

Completed

Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects

Hypercholesterolemia

Japan
Pfizer

Completed

A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.

Healthy

United States
University of Sheffield
Sheffield Teaching Hospitals NHS Foundation Trust

Completed

Does Using a 'Virtual Clinic' in Urogynaecology Improve Patient Experience and Reduce Cost?

Pelvic Floor Disorders

United Kingdom
Pfizer

Completed

Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin

Dyslipidemia | Hypercholesterolemia

United States
Pfizer
Arvinas Estrogen Receptor, Inc.

Recruiting

A Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood of Healthy Adults

Healthy

United States
Pfizer

Recruiting

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

Breast Cancer | Solid Tumors

China, United States, Mexico, Bulgaria, Spain, Brazil, Czechia, Argentina, South Africa
Shanghai Municipal Center for Disease Control and...
Shanghai Institute Of Biological Products

Unknown

Study on Effectiveness of 2-dose Live Attenuated Varicella Vaccine

Varicella

China
Seqirus
Department of Health and Human Services

Recruiting

Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults

Infections | Virus Diseases | Respiratory Tract Infections | Influenza, Human | Infection Viral

Philippines, United States
Zhejiang University

Completed

The Effects of Coenzyme A on Serum Lipids in Patients With Hyperlipidemia

Hyperlipoproteinemia
AbbVie

Completed

Relative Bioavailability of Two Lutikizumab Formulations and Pharmacokinetics, Safety, and Tolerability of Lutikizumab in Chinese Participants

Healthy Volunteers

United States
Aventure AB

Completed

Second Meal Effects of a Wholegrain Cereal Product on Blood Glucose Response

Blood Glucose Response

Sweden
Pfizer

Completed

A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.

Non-Alcoholic Fatty Liver Disease (NAFLD)

United States
Pfizer

Completed

A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese

Obesity | Overweight

United States
Harbour BioMed (Guangzhou) Co. Ltd.

Recruiting

A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITP

Primary Immune Thrombocytopenic Purpura

China
Lynk Pharmaceuticals Co., Ltd

Completed

A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

China

3

Subscribe